FONAR Corporation
NASDAQ:FONRMedical - Devices
+$0.00 today
- Market cap
- $117.76M
- Beta
- 0.95
- P/E (TTM)
- 17.6
- EPS (TTM)
- $1.08
Volume 0.00M
Average 0.08M
FONR Accounts Payables
Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.
FONAR CorporationNASDAQ: FONR
Accounts Payables · Q3 FY2026 · quarter ended Mar 2026
Accounts payables grows, but more slowly than its trailing trend
Q3 FY2026 accounts payables of $376K rose 38.2% year over year, behind the +335.4% change in trailing-twelve-month accounts payables. Over 3 fiscal years it compounded at +20.7% a year.
Context
- Accounts payables amounted to 0.5% of revenue in FY2025, up 0.3 pp from a year earlier.
- Accounts payables increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +38.2% toward the trailing-twelve-month pace of +335.4%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Payables history
USD · from the cash flow
- Latest · FY2025
- (553.56K) USD
- Year-over-year change
- -300.1%
| Period | Period end | Accounts Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-06-30 | (553.56K) | -300.1% |
| FY2024 | 2024-06-30 | 276.67K | +1305.5% |
| FY2023 | 2023-06-30 | 19.69K | +106.3% |
| FY2022 | 2022-06-30 | (314.77K) | -217.2% |
| FY2021 | 2021-06-30 | (99.22K) | — |
Accounts Payables vs competitors
How FONR compares with its peers on the latest reported figures
- Peers report in different currencies, so accounts payables is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +335.4% is the 3rd highest of 7, against a peer median of -28.4%.
- Accounts payables amounts to 1.0% of revenue for FONR, versus a peer median of 1.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | €6.32M EUR | — | +17.8% | 21552.6% | |
| LTM Mar 2026 | $2.33M USD | +1131.4% | — | 15.2% | |
| LTM Mar 2026 | $1.37M USD | -139.9% | +113.5% | 1.9% | |
| LTM Mar 2026 | $1.06M USD | +335.4% | +20.7% | 1.0% | |
ARTVArtiva Biotherapeutics, Inc. | LTM Mar 2026 | $1.01M USD | +447.4% | — | — |
| LTM Mar 2026 | $665K USD | -157.9% | +3.0% | 0.8% | |
| LTM Mar 2026 | $275K USD | +34.1% | +74.3% | 0.5% | |
| LTM Mar 2026 | $36K USD | -90.9% | -51.5% | — | |
| Peer median (excluding FONR) | — | -28.4% | +17.8% | 1.9% | |
Competitors are the stored peer set for FONR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Jun 2021 | FY2022 Jun 2022 | FY2023 Jun 2023 | FY2024 Jun 2024 | FY2025 Jun 2025 |
|---|---|---|---|---|---|
| Net Income | 13.67M | 17.23M | 12.13M | 14.1M | 10.67M |
| Depreciation & Amortization | 5.54M | 8.54M | 8.8M | 4.6M | 4.7M |
| Deferred Income Tax | 3.53M | 3.09M | 2.98M | 2.8M | 823.66K |
| Stock-Based Compensation | 83.28K | 0 | 0 | 0 | 0 |
| Change in Working Capital | (11.26M) | (14.21M) | (15.17M) | (8.62M) | (8.19M) |
| Accounts Receivables | (11.91M) | (5.56M) | (8.12M) | (11.62M) | (8.98M) |
| Inventory | (14.65K) | (696.4K) | (209.85K) | (145.78K) | (97.24K) |
| Accounts Payables | (99.22K) | (314.77K) | 19.69K | 276.67K | (553.56K) |
| Other Working Capital | 762.59K | (7.64M) | (6.86M) | 2.87M | 1.44M |
| Other Non-Cash Items | 7.53M | 642.77K | 5.73M | 1.22M | 3.26M |
| Operating Cash Flow | 19.09M | 15.3M | 14.47M | 14.09M | 11.26M |
| Capital Expenditures | (4.82M) | (4.63M) | (4.34M) | (822.85K) | (3.82M) |
| Acquisitions (Net) | 0 | (546K) | 0 | 0 | 0 |
| Purchases of Investments | (293) | (149) | (473) | (103.3K) | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | (163.71K) | (87.88K) | (119.57K) | 42.53K | (9.72K) |
| Investing Cash Flow | (4.82M) | (5.18M) | (4.34M) | (850.74K) | (3.8M) |
| Debt Repayment | (40.34K) | (37.24K) | (36.62K) | (44.9K) | (113.94K) |
| Common Stock Issued | 0 | 0 | 0 | 0 | 0 |
| Common Stock Repurchased | 0 | 0 | (1.76M) | (2.51M) | (1.81M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (6.57M) | (5.82M) | (5.78M) | (5.63M) | (5.55M) |
| Financing Cash Flow | (6.61M) | (5.86M) | (7.57M) | (8.18M) | (7.47M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 7.66M | 4.26M | 2.56M | 5.06M | (7.56K) |
| Free Cash Flow | 14.27M | 10.67M | 10.13M | 13.27M | 7.45M |
FONAR Corporation
NASDAQ:FONR
Intrinsic Alpha fair value
Locked
Current Price
$19.09
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.